View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 5, 2017

Takeda concludes enrolment in Phase III trial of TAK-003 for dengue

Japanese-based pharmaceutical firm Takeda Pharmaceutical has concluded enrolment in Phase III tetravalent immunisation against dengue efficacy study (TIDES) trial of TAK-003 to protect against all four strains of the dengue virus.

Japanese-based pharmaceutical firm Takeda Pharmaceutical has concluded enrolment in Phase III tetravalent immunisation against dengue efficacy study (TIDES) trial of TAK-003 to protect against all four strains of the dengue virus.

TAK-003 is the firm's live-attenuated tetravalent dengue vaccine candidate.

The double-blind, randomised and placebo-controlled Phase III trial enrolled 20,100 children and adolescents aged four to 16.

The trial will assess the efficacy, safety and immunogenicity in eight dengue-endemic countries in Latin America and Asia, including Brazil, Colombia, Panama, Dominican Republic, Nicaragua, Philippines, Thailand and Sri Lanka.

Takeda Global Vaccine business unit president Rajeev Venkayya said: “The successful enrolment of more than 20,000 children and adolescents in this Phase III trial, across several continents, and on an ambitious timeline, while maintaining a clear focus on quality and subject safety, reflects Takeda’s prioritisation of dengue and the substantial capabilities of our global organisation."

"The TIDES trial will evaluate two subcutaneous doses of TAK-003, given three months apart at Day 1 and Day 90."

The TIDES trial will evaluate two subcutaneous doses of TAK-003, given three months apart at Day 1 and Day 90.

The trial's primary objective is protection against virologically confirmed dengue of any severity and by any of the dengue serotypes.

The secondary endpoints will measure the efficacy of the vaccine to prevent the disease, hospitalisation and severe dengue associated with any dengue serotype.

The frequency and severity of adverse events (AEs) or serious AEs, seropositivity rate and geometric mean titers (GMTs) of neutralising antibodies in the immunogenicity subset will also be examined.

The initial results of the Phase III TIDES trial are expected to be reported next year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena